In mice, sporozoites of Plasmodium berghei delivered by mosquito bites are significantly more infectious than those transmitted by intravenous (i.v.) inoculation, as shown by Vaughan et al. (3). Using the chicken malaria P. gallinaceum in its natural host we obtained similar results. Sporozoites delivered by bites of two to five Aedes fluviatilis mosquitoes infected 100% of 1-week old chicks after prepatent periods (PPP) of 4 to 7 days, resulting in mortality of all birds. Sporozoites injected by syringe also cause malaria, although with lower parasitemia, longer PPP (∼11 days), and lower mortality (40% to 75%). Unlike P. berghei and all other sporozoites that infect mammals (which develop in the hepatocytes), P. gallinaceum sporozoites initially invade and develop within skin macrophages at the site of injection, rather than in other tissues.
The route by which sporozoites reach the hepatocytes is still debatable although their suggested transport via the lymphoid system (3) could well be through macrophages and/or Küppfer cells. The fact that P. berghei sporozoites enter and leave macrophages without being destroyed and that all attempts to cultivate the mammalian plasmodium sporozoites in hepatocytes have resulted in an extremely low percentage of infections supports this hypothesis. In addition, opsonized P. berghei sporozoites phagocytized by macrophages or Küpffer cells are destroyed.
In the presence of stage-specific monoclonal antibodies (MAb of ≥3 μg), sporozoite invasion and/or development in macrophages is totally abrogated (2), indicating that in vitro, the primary exoerythrocytic forms of P. gallinaceum developing inside macrophages are susceptible to being killed by antibodies. A direct correlation occurs between the protective effect of MAb in vitro and in vivo. Thus, in vitro suspensions of sporozoites plus MAb injected i.v. did not cause infection when we used the active MAb. All control chicks receiving sporozoites with medium or specific MAb with no activity in vitro had patent malaria and high parasitemia (2).
In the mouse model, high doses of passively transferred specific MAb antisporozoites inactivated sporozoites given i.v. but not through mosquito bites (3). This result strongly suggests the presence of protective mechanisms other than the blocking of sporozoite invasion into the host cell by MAb. Furthermore, in mice challenged with mosquito bites, protection hardly occurred, despite MAb transfer. We propose that macrophage killing of the opsonized sporozoites did not occur because the parasites were taken up by skin macrophages in the presence of low immunoglobulin G levels not sufficient to opsonize the parasites.
Finally, since high homology between DNA sequences of the circumsporozoite genes has been described for P. falciparum and P. gallinaceum (1) supporting a close phylogenetic relationship between these two species, it is quite possible that other similarities between the life cycles of avian and mammalian malaria parasites do exist. However, the role of macrophages in sporozoite transport and/or in antibody-mediated destruction of P. falciparum sporozoites and other mammalian malaria parasites is highly relevant to vaccine development and deserves further study, since antibodies are the key to antisporozoite protection.
REFERENCES
- 1.McCutchan T F, Kissinger J C, Touray M G, Rogers M J, Li J, Sullivan M, Braga E M, Krettli A U, Miller L H. Comparison of circumsporozoite proteins from avian and mammalian malarias: biological and phylogenetic implications. Proc Natl Acad Sci USA. 1996;93:11889–11894. doi: 10.1073/pnas.93.21.11889. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Ramirez A D, Rocha E M, Krettli A U. Antisporozoite antibodies with protective and non-protective activities: in vitro and in vivo correlation using Plasmodium gallinaceum, an avian model. J Eukaryot Microbiol. 1995;42:705–708. doi: 10.1111/j.1550-7408.1995.tb01620.x. [DOI] [PubMed] [Google Scholar]
- 3.Vaughan J A, Scheller L F, Wirtz R A, Azad A F. Infectivity of Plasmodium bergheisporozoites delivered by intravenous inoculation versus mosquito bite: implications for sporozoite vaccine trials. Infect Immun. 1999;67:4285–4289. doi: 10.1128/iai.67.8.4285-4289.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]